Virios Therapeutics Inc Stock News

- Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Study - - Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b study interim data readout is expected in Q4 2025 - - Cash on hand of $17.5M provides operational runway through Q1 2026 - ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX)...

ATLANTA, April 11, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders, today announced that it has received written confirmation from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stock...

ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders today announced it believes it has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1). DWTX Chairman a...

-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain (“CINP”) Phase 2b Trial -

Opioid-free and addiction-free pain treatment therapy could address $1.5B worldwide CINP market Opioid-free and addiction-free pain treatment therapy could address $1.5B worldwide CINP market

Proceeds from today's financing, when added to existing cash, fund operations through Q1 2026 The Company is planning to announce interim data from its ongoing Halneuron ® Phase 2b chemotherapy induced neuropathic pain (“CINP”) trial in Q4 2025 ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biopharmaceutica...